Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Ikapharmindo Putramas TbkISX:IKPM -2.53% 14-Day RSI is 50.28 as of Aug. 25, 2026. The stock has 1 warning sign investors should review. Among 699 Healthcare Providers & Services companies, PT Ikapharmindo Putramas Tbk ranks worse than 51.93% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
ISX:IKPM's 14-Day RSI is ranked worse than 51.93% of 699
companies
in the Healthcare Providers & Services industry
Industry Median: 49.59
vs ISX:IKPM: 50.28
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
PT Ikapharmindo Putramas Tbk 14-Day RSI Related Terms
For the Pharmaceutical Retailers subindustry, PT Ikapharmindo Putramas Tbk's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Ikapharmindo Putramas Tbk 14-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Ikapharmindo Putramas Tbk's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where PT Ikapharmindo Putramas Tbk's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Ikapharmindo Putramas Tbk (ISX:IKPM) has a 14-Day RSI of 50.28 as of Aug. 25, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on PT Ikapharmindo Putramas Tbk and its competitors. According to the industry distribution chart, PT Ikapharmindo Putramas Tbk ranks #363 out of 699 companies in the Healthcare Providers & Services industry, placing it in the top 51.9%.
Is PT Ikapharmindo Putramas Tbk's 14-Day RSI too high?
PT Ikapharmindo Putramas Tbk's current 14-Day RSI is 50.28. The Healthcare Providers & Services industry median 14-Day RSI is 49.59. PT Ikapharmindo Putramas Tbk's value of 50.28 is 1.4% above this industry median. Based on the distribution chart, PT Ikapharmindo Putramas Tbk ranks #363 out of 699 companies in the Healthcare Providers & Services industry, which is below the industry midpoint.
How does PT Ikapharmindo Putramas Tbk's 14-Day RSI compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, PT Ikapharmindo Putramas Tbk ranks #363 out of 699 companies for 14-Day RSI. This places PT Ikapharmindo Putramas Tbk in the lower half of its industry. The industry median 14-Day RSI is 49.59. PT Ikapharmindo Putramas Tbk's value of 50.28 is 1.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Healthcare Providers & Services company?
The median 14-Day RSI among Healthcare Providers & Services companies is 49.59, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Ikapharmindo Putramas Tbk's current 14-Day RSI of 50.28 is 1.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on PT Ikapharmindo Putramas Tbk and its competitors. For the Healthcare Providers & Services industry, the median 14-Day RSI is 49.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Ikapharmindo Putramas Tbk's current 14-Day RSI is 50.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Ikapharmindo Putramas Tbk stock overvalued right now?
PT Ikapharmindo Putramas Tbk (ISX:IKPM) has a current 14-Day RSI of 50.28. The current 14-Day RSI is 50.28 and 1.4% above the Healthcare Providers & Services industry median of 49.59. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For PT Ikapharmindo Putramas Tbk (ISX:IKPM), the current 14-Day RSI is 50.28 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PT Ikapharmindo Putramas Tbk is a factory and marketer of Pharmaceutical Products and Consumer Health Products located in Jakarta, Indonesia. Company has three reportable segments including non-pharma, pharma and contract manufacturing deriving key revenue from the Non- Pharma segment. It focuses on providing good quality and a diverse portfolio to the Indonesian market, with trusted brands in the Pharmaceutical Product Categories of Prescription Medicines, OTC, Nutraceuticals, Professional Hair Care Products and Baby Products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:IKPM has been successfully added to your 
